IgG Glycosylation: The Best Marker of Inflammaging

IgG glycosylation is the process by which complex sugar structures called glycans are enzymatically attached to Immunoglobulin G (IgG) — the most abundant antibody in human blood — fundamentally determining whether that antibody drives inflammation or suppresses it. Unlike glycation (the uncontrolled sugar-protein binding measured by HbA1c in diabetes), glycosylation is a tightly enzyme-controlled process that gives proteins their biological function. The distinction matters: glycation is a sign of metabolic damage; glycosylation is the molecular switch that governs immune behavior.

IgG carries glycans at a specific attachment site on its Fc region. When those glycans include subunits such as sialic acid and galactose, the antibody behaves in an anti-inflammatory manner. When those subunits are absent, leaving a shorter, truncated glycan structure, the same antibody activates pro-inflammatory pathways, including complement activation and antibody-dependent cellular cytotoxicity. A single monosaccharide change can convert IgG from anti-inflammatory to pro-inflammatory. This is not a subtle biochemical footnote; it is the molecular mechanism through which your immune system decides whether to protect or attack.

As a person ages, the balance shifts. Pro-inflammatory glycan structures accumulate on IgG, and the protective anti-inflammatory structures decline. The overall pattern of glycans across a person's IgG molecules (the IgG glycome) reflects the cumulative level of chronic inflammation in the body, making it one of the most informative biological age biomarkers available.

For a broader introduction to the molecules at the centre of this process, see our guide Glycans: The Sugars That Reveal Your Biological Age and Immune Health.

What is inflammaging, and how does IgG glycosylation measure it?

Inflammaging is the chronic, low-grade, systemic inflammation that accumulates with age and drives the development of age-related diseases. It is distinct from acute inflammation (the short-term immune response to infection or injury) and operates below the threshold of symptoms for years or decades before manifesting as cardiovascular disease, type 2 diabetes, or autoimmune conditions.

IgG glycosylation measures inflammaging directly: as the IgG glycome shifts toward pro-inflammatory structures, it captures the inflammatory biology that is actively accelerating biological aging. Because the IgG glycome integrates the effects of lifestyle, hormones, stress, and illness into a single measurable signal, it provides a more complete picture of immune aging than any single blood marker.

How does GlycanAge use IgG glycosylation to calculate biological age?

GlycanAge analyzes 29 distinct glycan structures attached to IgG from a finger-prick blood sample, measuring the ratio of pro-inflammatory to anti-inflammatory glycans to calculate a biological age score. IgG glycan changes follow a predictive pattern across the human lifespan that is consistent enough to have enabled the development of the first glycan-based biological age clock.

The result is not a single number in isolation: the GlycanAge report includes the patient's biological age alongside glycan indexes that reveal where chronic inflammation is concentrated and how it compares to population norms. Because IgG has a half-life of approximately 21 days, the glycome turns over relatively quickly, meaning meaningful biological changes can be detected within 3–6 months of a targeted intervention.

Is IgG glycosylation the same as measuring glycans generally?

IgG glycosylation is a specific subset of the broader human glycome, which is the complete set of glycan structures present across all proteins and cell surfaces in the body. Glycans coat every cell surface and are attached to the majority of human proteins, serving as a communication language between cells.

IgG was selected as the measurement target for GlycanAge for two reasons: it is the most abundant glycoprotein in blood plasma, making it technically accessible from a small sample, and its glycosylation directly determines the effector functions of the immune system, making it biologically meaningful, not merely convenient.

"For IgG glycosylation we know that it actually determines the effector functions of immunoglobulins — how changing a single monosaccharide in a glycan can completely convert the function of immunoglobulin from pro-inflammatory into anti-inflammatory."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

How is IgG glycosylation different from epigenetic clocks or DNA methylation tests?

IgG glycosylation measures active, current inflammation (the biological state of the immune system right now) whereas epigenetic clocks measure historical patterns of gene expression that change slowly and introduce substantial measurement noise.

The IgG glycome responds to lifestyle and medical interventions within 3–6 months, making it actionable for tracking whether a specific change is working. DNA tests, by contrast, reveal genetic potential and risk, providing a static readout that cannot tell you whether your biology is improving. IgG glycosylation sits downstream of genetics, integrating the effects of environment, behavior, and hormones into a measurable, modifiable signal.

For clinicians and individuals who want to know whether an intervention is producing real biological change, the responsiveness and stability of the IgG glycome makes it the most practical aging biomarker available.

Can IgG glycosylation change, or is it fixed by genetics?

IgG glycosylation is substantially modifiable through lifestyle and medical interventions, despite having a meaningful genetic component. Research has identified multiple genetic loci, including key glycosyltransferase genes such as B4GALT1, FUT8, ST6GAL1, and MGAT3, that influence how glycans are assembled on IgG, but these are regulatory genes, not a fixed assembly line. Environmental factors, including diet, exercise, hormones, and pharmacological interventions, can shift the IgG glycome toward a more anti-inflammatory profile.

Published research shows that people undergoing bariatric surgery have demonstrated reductions in glycan age of more than a decade, while caloric restriction and optimized exercise consistently produce statistically significant improvements across large cohorts. The practical implication is that IgG glycosylation is not destiny, but a dynamic readout of how your biology is responding to the choices you make.

What lifestyle factors most strongly influence IgG glycosylation?

Diet, exercise, hormones, and body weight are the most consistently documented influences on IgG glycosylation. Caloric restriction and weight loss, including through bariatric surgery, produce some of the most dramatic improvements in the IgG glycome. Exercise improves glycosylation, and research confirms that physical activity produces measurable anti-inflammatory shifts in IgG glycan composition, but overtraining reverses the benefit: GlycanAge's own clinical data shows that excessive physical load shifts the IgG glycome toward a pro-inflammatory profile, a pattern observed repeatedly in athletes.

Estrogen is a particularly strong regulator of IgG glycosylation in both women and men, which is why the perimenopausal transition, and the response to hormone replacement therapy, is one of the most clearly documented use cases for glycan monitoring. Because individual responses to diet and exercise vary significantly, IgG glycosylation functions as a personal feedback mechanism: it tells you whether a specific intervention is working for your biology, not just whether it works on average.

"With optimized hormone replacement, I've seen patients drop 20–25 years off their GlycanAge. This isn't just about relieving menopausal symptoms — it's about showing measurable improvements in biological age and inflammation. For the first time, we can prove the systemic benefits of HRT with objective data, and that changes the conversation from short-term relief to long-term health and longevity."

— Dr Joseph Raffaele, MD, Founder, Raffaele Medical

How stable is IgG glycosylation as a biomarker — can results fluctuate day to day?

IgG glycosylation is stable enough to filter short-term biological noise while remaining responsive to genuine biological change. This is a balance that generic blood panels cannot achieve.

Standard blood markers such as CRP or glucose fluctuate hourly and daily in response to meals, stress, and sleep, making them unreliable for tracking slow-moving biological processes like immune aging. The IgG glycome, by contrast, reflects the cumulative inflammatory state of the immune system over weeks and months, not hours. This stability means a change in GlycanAge result can be interpreted as a real biological shift rather than measurement artifact. This property makes it particularly valuable for clinicians monitoring intervention effectiveness over time.

"What I love about the GlycanAge test is that you can see changes within three months, and the results are quite stable. That's great for a biomarker of aging — the changes occur quickly, you can see them, monitor what you're doing, and alter your therapy if you need to."

— Dr Joseph Raffaele, MD, Founder, Raffaele Medical

When should someone test IgG glycosylation, and how often?

A baseline GlycanAge test is most informative when taken before initiating a significant lifestyle or medical intervention, whether that is starting HRT, changing diet and exercise protocols, beginning a supplement regimen, or managing a chronic condition. Retesting after 3–6 months captures whether the intervention has produced a measurable shift in the IgG glycome.

For individuals actively optimizing their health, annual retesting provides a longitudinal record of biological age trajectory. For clinicians, the retest cadence creates a structured monitoring framework: IgG glycosylation changes before symptoms emerge, meaning it can signal biological deterioration or improvement years ahead of clinical presentation. Prof. Lauc has described GlycanAge as a personal feedback tool for longevity — one that tells people what is working and what to adjust, rather than waiting for disease to confirm what the biology was already showing.

If you are ready to measure your IgG glycosylation and see where your biological age stands today, the GlycanAge at-home test kit ships to 65+ countries and includes a 1:1 Result Interpretation Call with a longevity specialist. Every result comes with a personalized analysis of your glycan profile and a clear plan for what to do next.

Order your GlycanAge test kit →

For functional medicine practitioners and longevity clinicians integrating IgG glycosylation into patient monitoring, visit the Healthcare Providers page to explore clinical workflows, partner pricing, and the evidence base behind glycan-based biological age testing.

External Sources

• https://www.nature.com/articles/316452a0 — Parekh RB, Dwek RA, Sutton BJ, et al. "Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG." Nature. 1985;316(6027):452–457.

• https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2000.tb06651.x — Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. "Inflamm-aging: An Evolutionary Perspective on Immunosenescence." Annals of the New York Academy of Sciences. 2000;908:244–254.

• https://www.sciencedirect.com/science/article/pii/S0008874918303253?via%3Dihub — Gudelj I, Lauc G, Pezer M. "Immunoglobulin G glycosylation in aging and diseases." Cell Immunology. 2018;333:65–79.

• https://insight.jci.org/articles/view/89703 — Ercan A, Kohrt WM, Cui J, et al. "Estrogens regulate glycosylation of IgG in women and men." JCI Insight. 2017;2(4):e89703.

• https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2019.01522/full — Tijardović M, Marijančević D, Bok D, Kifer D, Lauc G, Gornik O, Keser T. "Intense Physical Exercise Induces an Anti-inflammatory Change in IgG N-Glycosylation Profile." Frontiers in Physiology. 2019;10:1522.